Thromb Haemost 1997; 78(04): 1234-1236
DOI: 10.1055/s-0038-1657720
Rapid Communication
Schattauer GmbH Stuttgart

A Fast and Robust Dual-label Nonradioactive Oligonucleotide Ligation Assay for Detection of Factor V Leiden

Anders Chakravarty
The Department of Clinical Biochemistry and Genetics, Odense University Hospital, Odense, Denmark
,
Torben Stiig Hansen
The Department of Clinical Biochemistry and Genetics, Odense University Hospital, Odense, Denmark
,
Mogens Hørder
The Department of Clinical Biochemistry and Genetics, Odense University Hospital, Odense, Denmark
,
Søren Risom Kristensen
The Department of Clinical Biochemistry and Genetics, Odense University Hospital, Odense, Denmark
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 24. 1997

Accepted after revision 03. Juni 1997

Publikationsdatum:
12. Juli 2018 (online)

Summary

Activated protein C resistance is in almost all cases caused by the factor V Leiden mutation (FV:R506Q). Due to the high prevalence and clinical significance of the mutation reliable methods suited for processing large sets of samples are in demand. We here present the oligonucleotide ligation assay (OLA) with lanthanide labeled oligonucleotides for the detection of FV Leiden. The assay is based on time resolved fluorescence measurement of lanthanide labeled oligonucleotides (DELFIA: Delayed Enhanced Lanthanide Fluorescence Immuno Assay) and on the specificity of T-4 DNA Ligase to join two adjacent oligonucleotides only when the two are complementary to the PCR template at the ligation junction. The Europium/Samarium fluorescence pattern is specific for each of the three genotypes (G/G, G/A, A/A) and clearly separates the three genotypes. By using a wildtype probe (Samarium labeled) and a mutant-specific probe (Europium labeled) simultaneously an internal control of the assay is included in each reaction. The assay is simple to perform, can be partly automated and is ideal for processing large sets of samples.

 
  • References

  • 1 Dahlbäck B. The protein C anticoagulant system: Inherited defects as basis for venous thrombosis. Thromb Res 1995; 1: 01-43
  • 2 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by a poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
  • 3 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der VeldenPA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
  • 4 Alhenc GelasM, Gandrille S, Aubry M-L, Emmerich J, Fiessinger J, Aiach M. Unexplained thrombosis and factor V Leiden mutation. Lancet 1994; 344: 555-556
  • 5 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (Activated protein C resistance). Blood 1995; 85: 1504-1508
  • 6 Soubrier F, Fery I, Verdy E, René MN, Varsat B, Visvikis S, Siest G. The frequency of the factor V gene R506Q mutation varies between regions of France. Nouv Rev Fr Hematol 1995; 37: 175
  • 7 Rees DC, Cox M, Clegg JB. World distribution of factor V leiden. Lancet 1995; 346: 1133-1134
  • 8 Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein resistance: Molecular mechanisms based on studies using purified Gln506-Factor V. Blood 1995; 85: 3405-3411
  • 9 Cumming AM, Tai RC, Fildes S, Yoong A, Keeney S, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725-727
  • 10 Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C resistance in patients with lupus anticoagulant. Thromb Haemost 1995; 74: 797-798
  • 11 Trossaërt M, Conard J, Horellou MH, Elalamy I, Samama MM. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost 1996; 75: 521-522
  • 12 Kirschbaum NE, Foster PA. The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein resistance. Thromb Haemost 1995; 74: 874-878
  • 13 Beauchamp N, Daly MA, Cooper PC, Preston FE, Peake IR. Rapid two-stage PCR for detecting factor V G1691A mutation. Lancet 1994; 344: 694-695
  • 14 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
  • 15 Ridker PM, Hennekens CH, Lindpaintner K, Meir J, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for blood coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 322: 912-917
  • 16 Landegren U, Kaiser R, Sanders J, Hood L. A ligase-mediated gene detection technique. Science 1988; 241: 1077-1080
  • 17 Samiotaki M, Kwiatowski M, Parik J, Landegren U. Dual-color detection of DNA sequence variants by ligase-mediated analysis. Genomics 1994; 20: 238-242
  • 18 Zotz BJ, Maruhn-Debowski B, Scharf E. Mutation in the gene coding for coagulation factor V and resistance to activated protein C: Detection of the genetic mutation by oligonucleotide ligation assay using a semiautomated system. Thromb Haemost 1996; 76: 53-55
  • 19 Benson JM, Phillips DJ, Holloway BP, Evatt BL, Craig HooperW. Oligonucleotide ligation assay for detection of the factor V mutation (Arg506→Gln) causing protein C resistance. Thromb Res 1996; 83: 87-96